Literature DB >> 8306321

Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat.

M J McKeage1, F E Boxall, M Jones, K R Harrap.   

Abstract

This study compared the effect on sensory nerve conduction velocity in the hind limb of chronically treated age-matched rats of a novel lipophilic p.o. platinum complex [bisacetatoamminedichlorocyclohexylamine-platinum(IV)], with that of neurotoxic platinum complexes cisplatin and tetraplatin. Tetraplatin (i.p.) first caused slowing of sensory nerve conduction (-14.4% of controls; P < 0.05) at a dose (1 mg/kg) that was free of constitutional toxicity. Cisplatin (i.p.) first caused slowing of sensory nerve conduction (-17.5% of control; P < 0.05) at a dose (2 mg/kg) approximating the maximal tolerated dose. Bisacetatoamminedichlorocyclohexylamineplatinum(IV) (p.o.) showed no slowing of sensory nerve conduction either after 20.5 weeks of treatment at a dose (25 mg/kg) approximating the maximal tolerated dose or after 6 weeks of treatment at a dose (50 mg/kg) which eventually proved intolerable. In conclusion, p.o. bisacetatoamminedichlorocyclohexylamineplatinum(IV) shows a lack of neurotoxicity compared to parenterally administered cisplatin and tetraplatin at the maximal tolerated dose in rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306321

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Solvation of platinum anti-cancer drugs in methanol-water mixtures.

Authors:  J Burgess; D N Drasdo; M S Patel
Journal:  Biometals       Date:  1995-04       Impact factor: 2.949

Review 2.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 3.  New platinum agents. A comparison in ovarian cancer.

Authors:  L R Kelland; M J McKeage
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

4.  Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.

Authors:  D C Thompson; A Vaisman; M K Sakata; S D Wyrick; D J Holbrook; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.

Authors:  D Screnci; H M Er; T W Hambley; P Galettis; W Brouwer; M J McKeage
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.

Authors:  F I Raynaud; D E Odell; L R Kelland
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

7.  Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.

Authors:  D Screnci; M J McKeage; P Galettis; T W Hambley; B D Palmer; B C Baguley
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  Nucleolar damage correlates with neurotoxicity induced by different platinum drugs.

Authors:  M J McKeage; T Hsu; D Screnci; G Haddad; B C Baguley
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

9.  Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.

Authors:  S M F Jamieson; J Liu; T Hsu; B C Baguley; M J McKeage
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors.

Authors:  Eugenio Donato Di Paola; Silvia Alonso; Rosa Giuliani; Fabio Calabrò; Antonietta D'Alessio; Giovanni Regine; Linda Cerbone; Laura Bianchi; Andrea Mancuso; Sabine Sperka; Marcel Rozencweig; Cora N Sternberg
Journal:  Front Oncol       Date:  2012-11-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.